Literature DB >> 1279301

The relevance of cellular to clinical electrophysiology in classifying antiarrhythmic actions.

E M Vaughan Williams1.   

Abstract

The division of class I antiarrhythmic agents (sodium-channel blockers) into Ia, Ib, and Ic subgroups was based on clinical observations. Lidocaine, mexiletine, and tocainide (Ib) did not alter the QRS or H-V interval in sinus rhythm, but prolonged effective refractory period (ERP) in spite of some shortening of the J-T interval. Encainide, flecainide, and lorcainide (Ic) widened the QRS and prolonged H-V in sinus rhythm and at low concentration, but had little effect on the ERP or J-T. These clinical findings could be explained by fast onset/offset kinetics of Ib drugs, that when used in high concentrations, blocked most sodium channels during the action potential plateau; therefore, at the beginning of diastole, insufficient drug-free channels were available to support conduction, and the ERP was prolonged. Rapid dissociation of the drugs after repolarization insured that by the end of diastole most channels were again drug free, so that the QRS and H-V were normal. The Ic compounds were more potent, but of slow onset, so that a steady-state block of Na channels was not achieved until after many beats. Offset was also slow, so that a proportion of channels was persistently unavailable, Na current was reduced, and conduction slowed, causing widening of the QRS and lengthening of H-V. Because the remaining drug-free channels were normal, they recovered rapidly from inactivation, and the ERP was not prolonged. By clinical criteria, moricizine also must be classed as Ic, and its offset/onset kinetics are much slower than those of Ib drugs.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1279301

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Hyun Seok Hwang; Can Hasdemir; Derek Laver; Divya Mehra; Kutsal Turhan; Michela Faggioni; Huiyong Yin; Björn C Knollmann
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-01-26

2.  Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries.

Authors:  C-K Wong; H D White; R G Wilcox; D A Criger; R M Califf; E J Topol; E M Ohman
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

3.  Predicting QRS and PR interval prolongations in humans using nonclinical data.

Authors:  L Bergenholm; J Parkinson; J Mettetal; N D Evans; M J Chappell; T Collins
Journal:  Br J Pharmacol       Date:  2017-08-24       Impact factor: 8.739

4.  Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical Evaluation.

Authors:  Gül Erdemli; Albert M Kim; Haisong Ju; Clayton Springer; Robert C Penland; Peter K Hoffmann
Journal:  Front Pharmacol       Date:  2012-01-26       Impact factor: 5.810

5.  Molecular profiling of individual FDA-approved clinical drugs identifies modulators of nonsense-mediated mRNA decay.

Authors:  Jingrong Zhao; Zhelin Li; Ruchira Puri; Kelvin Liu; Israel Nunez; Liang Chen; Sika Zheng
Journal:  Mol Ther Nucleic Acids       Date:  2021-12-10       Impact factor: 8.886

6.  Exposure to sodium channel-inhibiting drugs and cancer survival: protocol for a cohort study using the QResearch primary care database.

Authors:  Caroline Fairhurst; Ian Watt; Fabiola Martin; Martin Bland; William J Brackenbury
Journal:  BMJ Open       Date:  2014-11-14       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.